TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model

KRAS/LKB1 (STK11) NSCLC metastatic tumors are intrinsically resistant to anti-PD-1 or PD-L1 immunotherapy. In this study, we use a humanized mouse model to show that while carboplatin plus pembrolizumab reduce tumor growth moderately and transiently, the addition of the tumor suppressor gene TUSC2,...

Descripción completa

Detalles Bibliográficos
Autores principales: Meraz, Ismail M., Majidi, Mourad, Shao, RuPing, Meng, Feng, Ha, Min Jin, Shpall, Elizabeth, Roth, Jack A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873264/
https://www.ncbi.nlm.nih.gov/pubmed/35210547
http://dx.doi.org/10.1038/s42003-022-03103-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873264/
https://www.ncbi.nlm.nih.gov/pubmed/35210547
http://dx.doi.org/10.1038/s42003-022-03103-7

Ejemplares similares